News
17h
TipRanks on MSNPDS Biotechnology Publishes Versamune® HPV Abstracts at ASCOPDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...
About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...
CHICAGO, October 15, 2024--(BUSINESS WIRE)--MAIA Biotechnology ... telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36 th EORTC-NCI-AACR Symposium ...
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...
MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...
Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...
SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”), a clinical-stage biotechnology company ... will present a Trials in Progress poster at the upcoming 2024 American ...
a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association ...
CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American ...
Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a ...
CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American ... Updated results” was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results